These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12463418)

  • 21. Formulation development for hydrophobic therapeutic proteins.
    Hawe A; Friess W
    Pharm Dev Technol; 2007; 12(3):223-37. PubMed ID: 17613886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Best Practices in Stability Indicating Method Development and Validation for Non-clinical Dose Formulations.
    Henry TR; Penn LD; Conerty JR; Wright FE; Gorman G; Pack BW
    AAPS J; 2016 Nov; 18(6):1418-1423. PubMed ID: 27600135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies.
    Banks DD; Hambly DM; Scavezze JL; Siska CC; Stackhouse NL; Gadgil HS
    J Pharm Sci; 2009 Dec; 98(12):4501-10. PubMed ID: 19388069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical Perspective on Opalescence and Liquid-Liquid Phase Separation in Protein Solutions.
    Raut AS; Kalonia DS
    Mol Pharm; 2016 May; 13(5):1431-44. PubMed ID: 27017836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of formulation variables on the stability of freeze-dried human growth hormone.
    Pikal MJ; Dellerman KM; Roy ML; Riggin RM
    Pharm Res; 1991 Apr; 8(4):427-36. PubMed ID: 1871037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical denaturation as a tool in the formulation optimization of biologics.
    Freire E; Schön A; Hutchins BM; Brown RK
    Drug Discov Today; 2013 Oct; 18(19-20):1007-13. PubMed ID: 23796912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
    Santana H; García G; Vega M; Beldarraín A; Páez R
    PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation and stability of cytokine therapeutics.
    Lipiäinen T; Peltoniemi M; Sarkhel S; Yrjönen T; Vuorela H; Urtti A; Juppo A
    J Pharm Sci; 2015 Feb; 104(2):307-26. PubMed ID: 25492409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.
    Sengupta P; Chatterjee B; Tekade RK
    Int J Pharm; 2018 May; 543(1-2):328-344. PubMed ID: 29635054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robustness index score: a new stability parameter for designing robustness into biologic formulations.
    Lonardo AJ; Srivastava A; Singh S; Goldstein J
    J Pharm Sci; 2012 Feb; 101(2):485-92. PubMed ID: 21976016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies.
    Majumdar R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Application of Modeling and Prediction to the Formation and Stability of Amorphous Solid Dispersions.
    DeBoyace K; Wildfong PLD
    J Pharm Sci; 2018 Jan; 107(1):57-74. PubMed ID: 28389266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.
    Toprani VM; Sahni N; Hickey JM; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
    Vaccine; 2017 Oct; 35(41):5471-5480. PubMed ID: 28551040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular origins of surfactant-mediated stabilization of protein drugs.
    Lee HJ; McAuley A; Schilke KF; McGuire J
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1160-71. PubMed ID: 21763375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein Aggregation in Frozen Trehalose Formulations: Effects of Composition, Cooling Rate, and Storage Temperature.
    Connolly BD; Le L; Patapoff TW; Cromwell MEM; Moore JMR; Lam P
    J Pharm Sci; 2015 Dec; 104(12):4170-4184. PubMed ID: 26398200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deliquescence of pharmaceutical systems.
    Mauer LJ; Taylor LS
    Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization of proteins in solid form.
    Cicerone MT; Pikal MJ; Qian KK
    Adv Drug Deliv Rev; 2015 Oct; 93():14-24. PubMed ID: 25982818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of ultraviolet, visible, and infrared light imaging in protein-based biopharmaceutical formulation characterization and development studies.
    Klijn ME; Hubbuch J
    Eur J Pharm Biopharm; 2021 Aug; 165():319-336. PubMed ID: 34052429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein. Calcitonine and human growth hormone in comparison.
    Cholewinski M; Lückel B; Horn H
    Pharm Acta Helv; 1996 Dec; 71(6):405-19. PubMed ID: 8997176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.